Stock Update (NYSE:STJ): St. Jude Medical Begins Landmark Clinical Study to Evaluate Effectiveness of Ablation Procedures for Treatment of Ventricular Tachycardia

[Business Wire] – St. Jude Medical, Inc. , a global medical device company, today announced the first patient enrollment in the STAR-VT clinical trial, a prospective, multi-center, randomized study evaluating the safety and . . . → Read More: Stock Update (NYSE:STJ): St. Jude Medical Begins Landmark Clinical Study to Evaluate Effectiveness of Ablation Procedures for Treatment of Ventricular Tachycardia Similar Articles: Stock Update: Boston Scientific Corporation (NYSE:BSX) – J&J demands $7.2 bln from Boston Scientific as trial begins Stock Update: St. Jude Medical Inc (NYSE:STJ) – St. Jude Medical Receives FDA Approval of TactiCath Quartz Contact Force Ablation Catheter for Treatment of Atrial Fibrillation Company Update (NYSE:STJ): St. Jude Medical Announces Launch of OPTISTM Integrated System